Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Teva
Covington
Accenture
Fuji
Johnson and Johnson

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,545,878

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,545,878 protect, and when does it expire?

Patent 8,545,878 protects INBRIJA and is included in one NDA.

This patent has forty-eight patent family members in fourteen countries.

Summary for Patent: 8,545,878
Title:Capsules containing high doses of levodopa for pulmonary use
Abstract: The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.
Inventor(s): Kee; Kevin (Somerville, MA), Penachio; Ernest D. (Haverhill, MA), Kamerkar; Abhijit (Boston, MA), Lipp; Michael M. (Framingham, MA), Batycky; Richard P. (Newton, MA)
Assignee: Civitas Therapeutics, Inc. (Chelsea, MA)
Application Number:13/679,245
Patent Claim Types:
see list of patent claims
Composition; Compound; Device; Dosage form;

Drugs Protected by US Patent 8,545,878

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
UBS
Argus Health
Teva
Fuji
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.